Jan. 4, 2022 – 2021 was a year of many healthcare challenges, but against this backdrop the Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research (CDER) approved 50 novel drugs and its Center for Biologics Evaluation and Research (CBER) approved 10 biological license applications (BLAs) (plus three source plasma products). CDER nearly […]
Read more
Feb. 17, 2020 — The Food and Drug Administration (FDA) began 2020 with continued momentum on drug approvals, a significant budget increase and a newly-confirmed Commissioner — Dr. Stephen Hahn – who has not yet presented his priorities for ongoing operations and new initiatives. But President Trump’s fiscal 2021 budget—released Feb. 10 – raises some […]
Read more